Rare case of Calciphylaxis of penis and distal digits: a report
Calciphylaxis is a rare, often fatal disease resulting from calcification of dermal arterioles and capillaries. Usually diagnosed in patients with end-stage renal disease, this disorder typically presents as necrotic, non-healing ulcers in acral or adipose areas. Smilnak et al. reported the case of an elderly man who was found to have calciphylaxis of the distal digits and penis, the latter of which is an uncommon site of disease that carries a particularly poor prognosis.
Case presentation: A 73-year-old African American man with multiple medical comorbidities including dialysis dependent end-stage renal disease presented with worsening painful, necrotic lesions on his glans penis and several distal digits over the last 2 months. The patient denied any new exposures or trauma to the areas of ulceration and had no history of tobacco use. The lesion on his glans penis was recently treated with a 1-week course of oral amoxicillin–clavulanic acid without improvement.
Physical examination revealed several small, exquisitely tender, necrotic ulcers with overlying black eschars on multiple finger pads; a gangrenous distal left third toe; and a foul-smelling lesion on the glans penis with overlying purulence. The digital lesions were cool to the touch and without surrounding edema or erythema.
Discovery of diffuse intravascular calcification on computed tomography, in addition to a markedly elevated calcium–phosphate product immediately prior to the onset of his ulcers, led to the diagnosis of calciphylaxis. His serum calcium and phosphorus were found to be 9.2 mg/ dL and 9.0 mg/dL (calcium phosphate product = 82.8 mg/dL). Product more than >70 mg/dL is consistent with calciphylaxis.
There is currently no consensus on the optimal treatment for calciphylaxis; management is guided by observational studies that advocate for a multimodal approach involving wound care, proper analgesia, infection prevention, and correction of serum calcium and phosphate levels. A trial of sodium thiosulfate (STS) is also recommended for all patients with calciphylaxis owing to its reported success in several case series. Therefore treatment with thrice weekly sodium thiosulfate (STS) (25 g) during dialysis was initiated.
Although the patient tolerated treatment without appreciable side effects, he experienced no improvement in the digital or penile lesions; in fact, he developed several more painful, necrotic ulcers corresponding with finger-stick blood glucose sample points. He was discharged home with plans to continue regular STS during dialysis. On follow-up, his wounds remained painful but showed no further progression; unfortunately, he died 3 months later after another prolonged hospitalization.
Even with appropriate management, calciphylaxis is a lethal disease: 6-month mortality rate is estimated to be 50%, with most patients dying from overwhelming infection. Involvement of the penis, as in this patient, is a particularly poor prognostic indicator, with 6-month mortality rates as high as 70%.
Overall, this case highlights the particularly poor prognosis associated with penile calciphylaxis. It also underscores the need for more effective management of the disease, especially in patients with multiple comorbidities.
Further reading:
Calciphylaxis of the penis and distal digits: a case report
Gordon Smilnak, Michael Jiang and Bijal Jain
Journal of Medical Case Reports (2022) 16:18
https://doi.org/10.1186/s13256-021-03231-4
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.